Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Psychol Med. 2019 Apr 15;50(4):644–652. doi: 10.1017/S0033291719000461

Table 1.

Demographics and clinical characteristics of the study sample at baseline assessment.

Measure Non-misusers (N=43) Misusers (N=57) Statistical test
Gender (M/F) χ2=2.13
 Female N (%) 27 (62.8) 34 (60.7)
Age (M ± SD) 57.0 ± 12.1 51.3 ± 11.8 t=2.37*
Race/Ethnicity χ2=2.15
 Caucasian N (%) 40 (93.0) 53 (94.6)
 African American N (%) - 1 (1.8)
 Latino N (%) 1 (2.3) 1 (1.8)
 Asian/Pacific Islander N (%) 1 (2.3) -
 Other 1 (2.3) 1 (1.8)
Primary pain condition χ2=4.41
 Lower back N (%) 22 (51.2) 30 (53.6)
 Joint/arthritis N (%) 5 (11.6) 10 (17.9)
 Head/neck N (%) 2 (4.7) 6 (10.7)
 Fibromyalgia N (%) 5 (11.6) 5 (8.9)
 Other 9 (20.9) 5 (8.9)
Clinical characteristics (M ± SD)
 COMM 9.2 ± 3.1 21.1 ± 7.1 t=10.29*
 Opioid use disorder symptoms 2.2 ± 2.3 4.1 ± 2.9 t=3.50*
 Morphine equivalent units per day 79.4 ± 103.1 89.9 ± 136.8 t=0.42
 BPI, Pain Severity 5.0 ± 1.4 5.2 ± 1.4 t=0.47
 BPI, Pain Interference 5.8 ± 1.8 6.3 ± 1.9 t=1.44

Note. Characterization of opioid non-misusers and misusers was based on the Current Opioid Misuse Measure (COMM), where the threshold for misuser was a score of ≥13.